<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353911</url>
  </required_header>
  <id_info>
    <org_study_id>5172-003</org_study_id>
    <nct_id>NCT01353911</nct_id>
  </id_info>
  <brief_title>Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003)</brief_title>
  <official_title>A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir
      (MK-5172) when administered in combination with peginterferon (Peg-IFN alfa-2b) and
      ribavirin in treatment-naïve participants with chronic hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amendment 5 allows treatment-naïve participants with chronic hepatitis C and compensated
      cirrhosis to be enrolled and receive grazoprevir 100 mg in combination with PegIFN alfa-2b
      and ribavirin, without a corresponding control arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants Achieving complete Early Viral Response (cEVR) in the Grazoprevir Treatment Arms</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing adverse events</measure>
    <time_frame>From first dose up to 72 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinued from study due to adverse events</measure>
    <time_frame>From first dose up to Week 44</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Sustained Viral Response 24 weeks After the End of All Study Therapy (SVR24)</measure>
    <time_frame>Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">368</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 100 mg + Peg-IFN alfa-2b + ribavirin for 12 weeks followed by 12 or 36 weeks of Peg-IFN alfa-2b + ribavirin based on response guided therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 200 mg + Peg-IFN alfa-2b + ribavirin for 12 weeks followed by 12 or 36 weeks of Peg-IFN alfa-2b + ribavirin based on response guided therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 400 mg + Peg-IFN alfa-2b + ribavirin for 12 weeks followed by 12 or 36 weeks of Peg-IFN alfa-2b + ribavirin based on response guided therapy Participants assigned to the 400 mg grazoprevir group have been unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN alfa-2b + ribavirin and will remain in the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 800 mg + Peg-IFN alfa-2b + ribavirin for 12 weeks followed by 12 or 36 weeks of Peg-IFN alfa-2b + ribavirin based on response guided therapy Participants assigned to the 800 mg grazoprevir group have been unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN alfa-2b + ribavirin and will remain in the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 week lead-in Peg-IFN alfa-2b + ribavirin then Boceprevir 800 mg + Peg-IFN alfa-2b + ribavirin for 24 weeks followed by 0 or 20 weeks of Peg-IFN alfa-2b + ribavirin based on response guided therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir</intervention_name>
    <description>Orally once daily in AM</description>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <description>four 200 mg capsules orally three times daily</description>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
    <other_name>Victrelis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Grazoprevir</intervention_name>
    <description>Orally once daily in AM</description>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Boceprevir</intervention_name>
    <description>four capsules orally three times daily</description>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-interferon alfa-2b</intervention_name>
    <description>1.5 μg/kg/week subcutaneous injection</description>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
    <other_name>PegIntron</other_name>
    <other_name>Peg-IFN alfa-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>300 mg to 700 mg orally twice daily</description>
    <arm_group_label>Grazoprevir 100 mg</arm_group_label>
    <arm_group_label>Grazoprevir 200 mg</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg</arm_group_label>
    <arm_group_label>Boceprevir 800 mg</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has previously documented chronic hepatitis C genotype 1 (CHC GT 1) infection

          -  Has hepatitis C virus (HCV) ribonucleic acid (RNA value) ≥10,000 IU/mL

          -  Body weight ≥40 kg (88 lbs) and ≤125 kg (275 lbs)

          -  Absence (no medical history or physical findings) of ascites, bleeding esophageal
             varices, hepatic encephalopathy, or other signs and symptoms of decompensated liver
             disease

          -  Had a liver biopsy within 3 years of screening or between screening and Day 1 with
             histology consistent with CHC and no evidence of cirrhosis or hepatocellular
             carcinoma or no other cause for chronic liver disease (for participants with
             compensated cirrhosis, any liver biopsy demonstrating cirrhosis regardless of length
             of time since biopsy)

          -  Female of childbearing potential or a male with female sexual partner who is of
             childbearing potential agrees to use two acceptable methods of birth control from at
             least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of
             study drug, or longer if dictated by local regulations

          -  For participants with compensated cirrhosis, evidence of cirrhosis without evidence
             of hepatocellular carcinoma (confirmed by ultrasound within 4 weeks prior)

        Exclusion Criteria:

          -  Is pregnant, breastfeeding, or plans to become pregnant or donate eggs

          -  Is human immunodeficiency virus (HIV) positive or known to be co-infected with
             hepatitis B virus

          -  Has received prior approved or investigational treatment for hepatitis C

          -  Has evidence of hepatocellular carcinoma or is under evaluation for hepatocellular
             carcinoma

          -  For participants with compensated cirrhosis: alphafetoprotein level of ≥100 ng/mL

          -  Has evidence of active or suspected malignancy, or a history of malignancy, within
             the last 5 years

          -  Has evidence or history of chronic hepatitis not caused by HCV

          -  Is diabetic and/or hypertensive with clinically significant ocular examination
             findings: retinopathy, cotton wool spots, optic nerve disorder, retinal hemorrhage,
             or any other clinically significant abnormality

          -  Has any known medical condition that could interfere with the patient's participation
             in and completion of the study

          -  Pre-existing psychiatric condition including but not limited to moderate or severe
             depression, suicidal or homicidal ideation or attempt, schizophrenia, psychosis,
             bipolar disorder, post traumatic stress disorder, or mania

          -  Is currently participating or has participated in a study with an investigational
             compound or device within 30 days of signing informed consent

          -  Member or family member of study staff
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug;147(2):366-76.e6. doi: 10.1053/j.gastro.2014.04.006. Epub 2014 Apr 12.</citation>
    <PMID>24727022</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 9, 2015</lastchanged_date>
  <firstreceived_date>May 12, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
